Pharmaceuticals
Everest Medicines to Hold New Corporate Strategy Online Conference Calls
SHANGHAI, Dec. 30, 2022 /PRNewswire/ -- Everest Medicines (HKEX: 1952), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced that the Company's management will host conference calls to introduce its new corpora...
2022-12-30 08:05
6134
Everest Medicines Announces China NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy
--Further regulatory support for accelerated approval of Nefecon following
NMPA's NDA acceptance with Breakthrough Therapy Designation—
SHANGHAI, Dec. 30, 2022 /PRNewswire/ -- Everest Medicines
2022-12-30 08:00
6652
Takeda Healthcare Philippines Inc Honored the Inspirational Award at the Asia Pacific Enterprise Awards 2022 Regional Edition
SINGAPORE, Dec. 28, 2022 /PRNewswire/ -- Enterprise Asia, the organizer of the Asia Pacific Enterprise Awards (APEA) 2022 Regional Edition, is pleased to recognize 25 exemplary business leaders and enterprises acrossAsia which excelled and showcased unparalleled resilience and growth despite theC...
2022-12-28 15:30
3060
Everest Medicines Commences Operations at its mRNA Vaccine Manufacturing Facility, Accelerating Evolution to a Fully-Integrated Biopharma
--Everest owns complete pharmaceutical and vaccine value chain from discovery, clinical development, manufacturing and commercialization-- --Localizes company's mRNA vaccine production, and helps meet urgent China and global demand for innovative vaccines and medicines-- SHANGHAI, Dec. 28, 2022 ...
2022-12-28 08:00
4939
Non-invasive in vitro diagnostic (IVD) test enables early detection of colorectal cancer
SAO PAULO, Brazil, Dec. 27, 2022 /PRNewswire/ -- The DNA Methylation Detection Kit for Human SDC2, ADHFE1 and PPP2R5C Genes (Real-Time PCR), the colorectal cancer early detection product under BGI's wholly-owned subsidiary BGI Biotechnology (Wuhan) Co., Ltd., has recently obtained the medical dev...
2022-12-27 23:59
2630
Brii Biosciences Provides Update on Strategic Clinical Development Progress
Topline Phase 2 data from multiple hepatitis B viral (HBV) infection functional cure combination studies expected in the first half of 2023 Initiation of Phase 2 postpartum depression (PPD) study planned for early 2023 to advance potential first-of-its-kind treatment U.S. FDA lifted clinical hol...
2022-12-27 20:00
5013
Hetero's 'Nirmacom' is world's first generic version of COVID-19 oral drug 'PAXLOVID' to receive WHO Prequalification
* Hetero's 'Nirmacom' (Nirmatrelvir), a generic version of Pfizer's COVID-19 oral antiviral drug 'PAXLOVID' is co-packaged with ritonavir tablets * With the launch of Nirmacom, Hetero aims to expand access of the ground-breaking antiviral in 95 LMICs including India HYDERABAD, India, Dec. 27, ...
2022-12-27 10:00
5212
Ablaze Pharmaceuticals and Yonghe Pharma Initiate Development and Manufacturing Services Agreement for Targeted Radiopharmaceutical Therapies
SHANGHAI, Dec. 27, 2022 /PRNewswire/ -- Ablaze Pharmaceuticals ("Ablaze") announced the initiation of a development and manufacturing services agreement with Yonghe Pharmaceutical Technology Co., Ltd. ("Yonghe") to develop series of targeted radiopharmaceutical therapy ("TRT") products. Under the...
2022-12-27 10:00
4349
Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-037 (CD73 Inhibitor) in Combination with KEYTRUDA® (pembrolizumab)
- ATG-037 is Antengene's oral small molecule CD73 inhibitor; KEYTRUDA® (pembrolizumab) is MSD's anti-PD-1 therapy - The clinical trial collaboration will focus on evaluating ATG-037 as a monotherapy and in combination with KEYTRUDA® for the treatment of locally advanced or metastatic solid tumors...
2022-12-27 08:30
4123
Superior Neutralizing Antibody Titer Levels Against Omicron BF.7 And BA.2.75 Of The Company's Two-Component Recombinant COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine
TAIZHOU, China, Dec. 26, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that positive results were achieved for its sequential booster vaccination Phase II study of the recombinant two-component COVID-19...
2022-12-26 11:33
5859
Fosun International Granted Three Awards from Global Banking and Finance Review in the United Kingdom
HONG KONG, Dec. 23, 2022 /PRNewswire/ -- On 23 December 2022, Fosun International was notified byGlobal Banking and Finance Review, a famous financial magazine in theUnited Kingdom, that Fosun International was granted three awards, namely "Brand of the Year Awards - Holding Group Brand of the Y...
2022-12-23 10:52
5313
JUNIPER BIOLOGICS WINS M&A AWARD 2022 BY ACQUISITION INTERNATIONAL
Best Cell & Gene Therapy Acquisition 2022: Juniper Biologics/Kolon Life Science
SINGAPORE, Dec. 23, 2022 /PRNewswire/ -- Singapore-headquartered Juniper
Biologics Pte Ltd
2022-12-23 09:35
3734
Everest Medicines' Licensing Partner Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis
SHANGHAI, Dec. 22, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) has received acceptance from the U.S. Food and Drug Administration (FDA) for review a New Drug Application (NDA) for etrasimod for individuals living with ...
2022-12-22 08:00
5655
ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU along with Theranostic Pipeline Advances
* Complete data from global Phase III ZIRCON study of Telix's investigational imaging agent TLX250-CDx in clear cell renal cell carcinoma (ccRCC) will be presented at American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium (ASCO GU) inFebruary 2023 * Telix pipeline...
2022-12-22 06:04
3334
CGTN: 'New Approaches': How China stepped up its COVID-19 treatments
BEIJING, Dec. 21, 2022 /PRNewswire/ -- China has been racing against the clock in developing COVID-19 drugs while promoting vaccination – one for saving lives and the other for providing broad protection. While the stringent COVID-19 containment measures of the past three years helpedChina evade...
2022-12-21 18:51
3770
Medidata awarded International Innovation Award for Medidata Sensor Cloud
SINGAPORE, Dec. 21, 2022 /PRNewswire/ -- For the third consecutive year, Medidata, a Dassault Systèmes company, was awarded the International Innovation Award. This year, the Medidata Sensor Cloud won the award under the Service and Solution category. Sensor Cloud provides cutting-edge data inges...
2022-12-21 14:44
2718
Ascletis' NASH Drug ASC41(THRβ) Phase II Enrollment is Progressing as Planned
HANGZHOU and SHAOXING, China, Dec. 21, 2022 /PRNewswire/ -- The enrollment of the 52-week Phase II clinical trial of thyroid hormone receptor β (THRβ) agonist ASC41 developed in house by Gannex Pharma Co., Ltd., a wholly owned subsidiary of Ascletis Pharma Inc. (HKEX: 1672, "Ascletis"), for tr...
2022-12-21 08:00
4028
Sirnaomics Announces Interim Data from Phase I Clinical Trial of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors
First three out of five cohorts pass safety requirements, allowing the Company to dose additional cohorts to assess safety, tolerability, pharmacokinetics and anti-tumor activity HONG KONG, GERMANTOWN, Md., and SUZHOU, China, Dec. 21, 2022 /PRNewswire/ -- Sirnaomics Ltd.(Stock Code: 2257.HK) (th...
2022-12-21 00:39
4673
AstraZenca, G42 Healthcare enter strategic partnership to manufacture pharmaceutical products in Abu Dhabi
ABU DHABI, UAE, Dec. 20, 2022 /PRNewswire/ -- Building on the ongoing efforts of the Department of Health –Abu Dhabi (DoH) in spearheading Abu Dhabi's healthcare ecosystem, AstraZeneca, a science-led biopharmaceutical and one of the top 10 biopharma companies globally, and G42 Healthcare, an AI-p...
2022-12-20 23:16
3010
Kira Pharmaceuticals Announces Clearance to Initiate Phase 2 Evaluation of KP104 in IgA Nephropathy (IgAN) and Complement 3 Glomerulopathy (C3G) in China and Australia
CAMBRIDGE, Mass., Dec. 20, 2022 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, announced today that the Chinese National Medical Products Administration (NMPA) and the Australian Therapeutic ...
2022-12-20 20:00
3944
Week's Top Stories
Most Reposted
Futurise Impact Report 2025 Highlights Progress in Regulatory Innovation Future-Ready Technologies
[Picked up by 272 media titles]
2026-09-09 13:26
Novo Holdings invests in ForYou Medical to support global growth in advanced wound care manufacturing
[Picked up by 264 media titles]
2026-09-10 15:00New ASEAN Study Reveals Businesses Are Rethinking Hiring and Investment as Growth Priorities Shift
[Picked up by 260 media titles]
2026-09-10 07:45
AKSADRON Releases Impact Report 2025, Showcasing the Growth of Malaysia's Drone Sports Talent Ecosystem
[Picked up by 255 media titles]
2026-09-14 15:36
Qunabox Group Opens '99 Quna Festival,' Debuting Consumer-Facing Physical AI Entertainment
[Picked up by 251 media titles]
2026-09-09 11:01Most Read
ALLSWIFIT Introduces ActiveRise+, a Stable Carbon-Plate Running Shoe Built to Help Everyday Runners Train Smarter and Run Stronger
2026-09-11 21:00
10276
